Successful Antiviral and Antituberculosis Treatment With Pegylated Interferon-alfa and Ribavirin in a Chronic Hepatitis C Patient With Pulmonary Tuberculosis

被引:17
|
作者
Tsai, Ming-Chao [1 ]
Lin, Meng-Chih [2 ]
Hung, Chao-Hung [1 ]
机构
[1] Chang Gung Univ, Kaohsiung Med Ctr, Chang Gung Mem Hosp, Coll Med,Div Hepatogastroenterol,Dept Internal Me, Kaohsiung, Taiwan
[2] Chang Gung Univ, Kaohsiung Med Ctr, Chang Gung Mem Hosp, Coll Med,Div Pulm & Crit Care Med,Dept Internal M, Kaohsiung, Taiwan
关键词
chronic hepatitis C; peginterferon alfa-2a; pulmonary tuberculosis; sustained virological response; PLUS RIBAVIRIN; THERAPY; MANAGEMENT; INFECTION; TAIWAN;
D O I
10.1016/S0929-6646(09)60400-9
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Pulmonary tuberculosis is a rare side effect of antiviral treatment for chronic hepatitis C. We present the case of 55-year-old woman with chronic hepatitis C, who developed pulmonary tuberculosis after receiving 8 weeks of peginterferon alfa-2a plus ribavirin therapy. Antituberculous treatment was started and antiviral agents were given continually at adjusted doses. Her symptoms of cough with blood-tinged sputum improved I month after antituberculous therapy. Treatment for hepatitis C and pulmonary tuberculosis were completed after 6 months. At 6 months after antiviral therapy, a sustained virological response was achieved and follow-up chest radiography showed a marked regressive change. This is believed to be the first case report of complete remission from hepatitis C and pulmonary tuberculosis treated concurrently with antiviral and antituberculous agents. [J Formos Med Assoc 2009; 108(9):746-750]
引用
收藏
页码:746 / 750
页数:5
相关论文
共 50 条
  • [21] Extrahepatic Manifestations of Chronic Hepatitis C and their Influence on Response to Treatment with Pegylated Interferon Alfa-2a and Ribavirin
    Fabri, Milotka
    Ruzic, Maja
    Lendak, Dajana
    Preveden, Tomislav
    Fabri, Izabella
    Petric, Vedrana
    SRPSKI ARHIV ZA CELOKUPNO LEKARSTVO, 2013, 141 (5-6) : 320 - 324
  • [22] Interferon alfa (pegylated and non-pegylated) and ribavirin for the treatment of mild chronic hepatitis C: a systematic review and economic evaluation
    Shepherd, J.
    Jones, J.
    Hartwell, D.
    Davidson, P.
    Price, A.
    Waugh, N.
    HEALTH TECHNOLOGY ASSESSMENT, 2007, 11 (11) : 1 - +
  • [23] Pegylated interferon alfa-2b pen device and ribavirin treatment for patients with chronic hepatitis C: an evaluation of patient satisfaction
    Aggelopoulou-Tiga, Paraskevi
    Dimitroulopoulos, Dimitrios
    Kaligeros, Konstantinos
    Koutsounas, Sotirios
    Kouroumalis, Elias
    Diamanti, Helen
    Ioannidou, Panagiota
    Kountouras, Jannis
    Papaioannou, Christos
    Dimopoulou, Maria
    Giannoulis, Grigoris
    Ketikoglou, Ioannis
    Protopapas, Andreas
    Bassaris, Harry
    Delis, Vassilios
    Karatapanis, Stylianos
    Manolakopoulos, Spilios
    Mimidis, Konstantinos
    Nikolaou, Antonios
    Thomopoulos, Konstantinos
    Tzelas, Georgios
    Tsianos, Epameinondas
    Kardasi, Maria
    Perperas, Antonios
    EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 2010, 22 (09) : 1058 - 1065
  • [24] Dermatological Manifestations of Pegylated Interferon Alfa2a and Ribavirin in Patients with Chronic Hepatitis C
    Sikander, Irum
    Bano, Razia
    Humaira, Mona
    Memon, Asadullah
    Shaikh, Muzaffar
    Ghani, M. Hanif
    Ansari, Shuaib
    PAKISTAN JOURNAL OF MEDICAL & HEALTH SCIENCES, 2021, 15 (02): : 265 - 267
  • [25] Fatal cardiomyopathy associated with pegylated interferon/ribavirin in a patient with chronic hepatitis C
    Condat, Bertrand
    Asselah, Tarik
    Zanditenas, David
    Estampes, Bertrande
    Cohen, Ariel
    O'Toole, Dermot
    Bonnet, Joelle
    Ngo, Yann
    Marcellin, Patrick
    Blazquez, Martine
    EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 2006, 18 (03) : 287 - 289
  • [26] Efficacy and safety of ribavirin plus pegylated interferon alfa in geriatric patients with chronic hepatitis C
    Hu, C. -C.
    Lin, C. -L.
    Kuo, Y. -L.
    Chien, C. -H.
    Chen, S. -W.
    Yen, C. -L.
    Lin, C. -Y.
    Chien, R. -N.
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2013, 37 (01) : 81 - 90
  • [27] Health-related quality of life in Greek chronic hepatitis C patients during pegylated interferon and ribavirin treatment
    Sinakos, E.
    Gigi, E.
    Lalla, T.
    Bellou, A-L
    Sykja, A.
    Orphanou, E.
    Vrettou, E.
    Tsapas, V
    Raptopoulou, M.
    HIPPOKRATIA, 2010, 14 (02) : 122 - 125
  • [28] Leukocyte interferon-α and ribavirin for treatment of chronic hepatitis C patients intolerant to pegylated-interferon
    Adinolfi, Luigi E.
    Durante-Mangoni, Emanuele
    Salzillo, Marta
    Marrone, Aldo
    Tripodi, Marie-Francoise
    Restivo, Luciano
    Merola, Antonietta
    Zampino, Rosa
    Ruggiero, Giuseppe
    INTERNAL AND EMERGENCY MEDICINE, 2009, 4 (06) : 485 - 490
  • [29] Extended treatment with interferon and ribavirin in a hemodialysis patient with chronic hepatitis C
    Vigani, Aline Gonzalez
    Pavan, Maria H. P.
    Tozzo, Raquel
    Goncales, Eduardo S. L.
    Lazarini, Maria S. K.
    de Oliveira, Alexandre Macedo
    Goncales, Fernando L., Jr.
    BRAZILIAN JOURNAL OF INFECTIOUS DISEASES, 2010, 14 (02) : 193 - 196
  • [30] A multidisciplinary support programme increases the efficiency of pegylated interferon alfa-2a and ribavirin in hepatitis C
    Antonio Carrion, Jose
    Gonzalez-Colominas, Elena
    Garcia-Retortillo, Montserrat
    Canete, Nuria
    Cirera, Isabel
    Coll, Susanna
    Dolors Gimenez, Maria
    Marquez, Carmen
    Martin-Escudero, Victoria
    Castellvi, Pere
    Navines, Ricard
    Ramon Castano, Juan
    Anton Galeras, Josep
    Salas, Esther
    Bory, Felipe
    Martin-Santos, Rocio
    Sola, Ricard
    JOURNAL OF HEPATOLOGY, 2013, 59 (05) : 926 - 933